NRX Pharmaceuticals Q3 EPS $(0.07) Beats $(0.12) Estimate
Portfolio Pulse from Benzinga Newsdesk
NRX Pharmaceuticals (NASDAQ:NRXP) reported a Q3 EPS loss of $(0.07), surpassing the consensus estimate of $(0.12) by 41.67%. The reported loss shows a 50% improvement from the $(0.14) per share loss in the same quarter of the previous year.
November 14, 2023 | 2:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NRX Pharmaceuticals reported a smaller-than-expected loss per share in Q3, indicating a positive earnings surprise and an improvement from the previous year.
NRX Pharmaceuticals' reported earnings beat is likely to be viewed positively by investors, as it indicates better-than-expected financial performance and could lead to increased investor confidence and upward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100